Docket Number:12A-1010829
Inventor:Yi-Ling Lin
IP Status:TW I484963、US pending
Abstract:
Prochlorperazine (PCZ) is a drug approved by FDA to treat nausea and vomiting. We find that dengue virus (DENV) replication was greatly reduced in cells treated with noncytotoxic doses of PCZ. In a mouse model, PCZ alleviated the lethality of DENV infection. Besides, PCZ also exhibits antiviral effect against another flavivirus, Japanese encephalitis virus (JEV) infection.
Fields of Application:
The FDA-approved drug PCZ has a previously unknown antiviral function and could be further evaluated as a potential therapeutic strategy against infection of DENV, JEV, and probably other flaviviruses such as West Nile virus (WNV).
Advantages when compared to the existing technologies:
So far, no specific antiviral agent inhibiting JEV and DENV replication is available and supportive care and symptomatic treatment are commonly used in JE and dengue patients. Our finding that PCZ, a FDA-approved drug to treat nausea and vomiting, has potent antiviral activity against DENV and JEV replication is novel and significant, because treatment of JE and dengue patients with PCZ may have two benefits, reduce viral replication and relieve symptoms. Thus, PCZ is worthy of further clinical study to evaluate its effect on treating patients with JEV, DENV and probably also with WNV infection.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
